ANAHEIM, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Gala Global, Inc. (OTC:GLAG), a publicly-traded development firm specializing in equity investments, debt financing and mergers and acquisitions in the biotech industry, has completed the acquisition of a majority equity position in Controlled Environment Genomics Inc., an Akron, Ohio based start-up biotechnology company focused on the development and commercialization of computer controlled digital plant cloning incubators for use in the agricultural and biopharmaceutical industries.
Gala Global targets investments in companies commercializing biotechnologies, including indoor agriculture, molecular biology, genetics, and biopharmaceuticals.
“We are concentrating Gala Global’s focus on the biotech industry,” said Gala Global CEO Timothy Madden. “This allows us to expand our portfolio of companies now successfully commercializing technologies and services that create efficiencies and improvements, while simultaneously reducing production costs and improving economic growth in the industry.”
Said Madden: “Gala Global’s greatest potential exists in acquiring high-growth-rate companies that have intellectual property rights to commercially proven disruptive technologies, which are rapidly changing and expanding the biotech industry.”
Gala Global is now working with technology partner GenoBreeding Inc., on developing breeding tools such as molecular markers to enable productive plant breeding decisions and processes that achieve top-tier plant performance in a sustainable manner.
Another Gala Global technology partner is Controlled Environment Genomics, Inc. (CEG), an Akron, Ohio genomics company recently acquired by Gala Global. CEG specializes in digital plant gene sequencing, editing, and cloning technologies.
CEG’s state-of-the-art genomics technology enables GenoBreeding to digitally sequence the genomes of the most desirable plant varieties based on flavor and nutrition, so the desirable traits can be used to improve the most desirable commercial varieties with traits like increased yield, and quality, thus enhancing consumer demand for the product and increasing profitability.
GenoBreeding is also developing a proprietary digital genetic database that will be used as an online cloud based library of digitally sequenced genomes and phenotypic (chemical composition) information on all existing and new plant varieties.
CEG Inc. proprietary digital plant cloning technology will enable GenoBreeding’s geneticists to select the best plant varieties to hybridize, improving and increasing crop quality and yields, by combining the very best genetics, maximizing the variation of positive inherited characteristics in each variety.
About Gala Global Inc.
Gala Global, Inc., Anaheim, Calif., is a publicly-traded startup development company specializing in equity investments, debt financing and mergers and acquisitions (M&A) in the biotech industry. Gala Global’s professional services group provides operational services and technologies that drive efficiencies in the market. Gala Global has industry-leading expertise helping companies make the most of their potential in an emerging market. Gala Global website: www.galaglobalinc.com .
About Clipius Technologies Inc.
Clipius Technologies Inc., a Carbondale, Ill.-based manufacturer of genomic technologies, will direct development in the digital plant cloning incubators project. Clipius is headed by Dr. Ajay Mahajan, president. Mahajan, currently a tenured professor in the mechanical engineering and biomedical engineering departments at The University of Akron in Ohio, now chairs the finance committee for the Akron BioInnovation Fund II (ABFII) for the City of Akron. He was the associate vice president for innovation for the University and the associate dean for research in the College of Engineering until 2015.
About GenoBreeding Inc.
GenoBreeding Inc. a subsidiary of Greengro Technologies, Inc. , (OTC:GRNH) Anaheim, Calif., formed in early 2017 to direct a Greengro initiative intended to bring to the cannabis market cutting-edge plant varieties through the application of modern plant breeding technologies conducive to increased consumer demand and improved production profitability.
Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.
Development Team:
Dr. Ajay Mahajan , President Clipius Technologies Inc., is currently a tenured professor in the mechanical engineering and biomedical engineering departments at The University of Akron in Ohio. He is currently the chair of the finance committee for the Akron BioInnovation Fund II (ABFII) for the City of Akron. He was the associate vice president for innovation for the University and the associate dean for research in the College of Engineering until 2015.
Before coming to Akron he worked at Southern Illinois University Carbondale. He is currently a board member for the Bell Chapter of the Hawkins Foundation that advances orthopedic medicine and outcomes for patients through research and education. In the past he has worked with NASA, US DoD, US Federal Highway, as well as companies such as Timken, Caterpillar and Medtronic. He has also worked with two Formula One teams (Renault F1 and Toyota F1).
He is the co-founder and president of Clipius Technologies, a high-tech genomics device company, and serves on the boards of many organizations/ companies. He has developed numerous biomedical devices and has also run numerous cadaver labs for Medtronic while testing that company’s new devices for FDA approval and marketing claims. In NE Ohio, he has been a champion for increasing/improving the technology and innovation ecosystem.
Two years ago, he served on President Barack Obama’s Advanced Manufacturing Partnership (AMP2.0) initiative at the White House.
Wil Hemker is an R&D scientist and entrepreneur experienced in new product development, identifying advanced technology, IP assessment, and leading partnership teams to commercialize innovative products. His successes include: commercializing IP protected products using advanced technology for the environmental, food production, new product materials for over-the-counter (OTC) dermatological and anti-microbial marketplaces.
Wil is a senior entrepreneur fellow at the University of Akron Research Foundation (UARF) commercializing new materials and technologies into environmental, food production and biomedical markets. Wil holds a BS in chemistry from Bowling Green State University and a MS in Food Science from The Ohio State University. He is very active in the food movement including ways to increase nutrition in schools, hospitals and institutions.
Timothy Madden , a serial entrepreneur, inventor and business executive, has positioned his companies as leaders in the U.S. indoor agriculture industry. His extensive knowledge of plant science, greenhouses, integrated renewable energy systems and fully automated controlled environment agriculture (CEA) technologies provides his companies with significant competitive advantages in their respective markets.
Tim’s education and experience include a degree in computer electronics from Fortis College, ten years as founder and President of Biodynamics Inc., and three years as founder and manager of On Point Hydroponics LLC, currently serving as CEO of Gala Global Inc.
As part of his early education, Tim studied the work of Dr. Rudolf Steiner, a scientist, philosopher and inventor of commercial-scale organic agriculture. Steiner published his work in 1924 to combat the rapid worldwide decline in crop nutritional value and fertility occurring in the 20 th century as a result of monoculture practices and the overuse of pesticides. The science of indoor agriculture is founded on the need for crop production as a closed loop agricultural system, self-contained and self-sustaining, creating and maintaining life, free of external contaminants and the production of pollution. Tim has helped make Dr. Steiner’s vision a reality in his own work through entrepreneurship and the invention and development of proprietary controlled environment technologies operated by artificial intelligence (AI) technologies and powered by integrated renewable energy systems.
Contact: Timothy J. Madden, CEO Gala Global, Inc. tim@galaglobalinc.com www.galaglobalinc.com (714) 660-3081
